Technical Analysis for PRTG - Portage Biotech Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | 10.12% | |
| NR7-2 | Range Contraction | 10.12% | |
| Wide Bands | Range Expansion | 10.12% | |
| Gapped Up | Strength | 10.12% | |
| Oversold Stochastic | Weakness | 10.12% | |
| NR7 | Range Contraction | 13.12% |
| Alert | Time |
|---|---|
| Down 5% | about 21 hours ago |
| Down 3% | about 21 hours ago |
| Fell Below Previous Day's Low | about 21 hours ago |
| Down 2 % | about 21 hours ago |
| Down 1% | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/26/2024
Portage Biotech Inc. Description
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Immunology Solid Tumors Immune System Antibodies Antiviral Drug Interferon Acute Kidney Injury Biotechnology Products Natural Killer T Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 40.8 |
| 52 Week Low | 2.098 |
| Average Volume | 1,158,428 |
| 200-Day Moving Average | 6.39 |
| 50-Day Moving Average | 5.85 |
| 20-Day Moving Average | 4.94 |
| 10-Day Moving Average | 4.30 |
| Average True Range | 0.69 |
| RSI (14) | 44.13 |
| ADX | 20.66 |
| +DI | 23.75 |
| -DI | 19.44 |
| Chandelier Exit (Long, 3 ATRs) | 5.04 |
| Chandelier Exit (Short, 3 ATRs) | 5.87 |
| Upper Bollinger Bands | 6.47 |
| Lower Bollinger Band | 3.41 |
| Percent B (%b) | 0.38 |
| BandWidth | 61.86 |
| MACD Line | -0.48 |
| MACD Signal Line | -0.44 |
| MACD Histogram | -0.039 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.03 | ||||
| Resistance 3 (R3) | 5.93 | 5.36 | 5.78 | ||
| Resistance 2 (R2) | 5.36 | 4.99 | 5.40 | 5.70 | |
| Resistance 1 (R1) | 4.96 | 4.76 | 5.16 | 5.06 | 5.62 |
| Pivot Point | 4.39 | 4.39 | 4.49 | 4.43 | 4.39 |
| Support 1 (S1) | 3.99 | 4.02 | 4.19 | 4.09 | 3.52 |
| Support 2 (S2) | 3.42 | 3.79 | 3.46 | 3.44 | |
| Support 3 (S3) | 3.02 | 3.42 | 3.36 | ||
| Support 4 (S4) | 3.12 |
